Pulmonx Corporation

September 15, 2016September 15, 2016

Homogeneous Emphysema Patients Could Benefit from Zephyr Endobronchial Valve, Study Shows

Emphysema, News

Pulmonx recently announced positive results from the IMPACT (NCT02025205) study assessing the company’s proprietary Zephyr endobronchial valve (EBV), showing that patients with homogeneous emphysema benefit from the treatment. The Zephyr EBV is ... Read more

May 20, 2016May 20, 2016

Follow-up Data from Study of EBV Treatment in Emphysema Patients Shows Lasting Benefits

Emphysema, News

Pulmonx Corporation reported positive one-year data from the STELVIO trial, the first randomized study evaluating the Zephyr Endobronchial Valve (EBV) in people with severe emphysema, who were selected using the diagnostic Chartis System to identify ... Read more